Bivalent COVID-19 mRNA booster doses in persons aged ≥12 years were associated with frequent injection site (60.8%) and systemic (54.8%) reactions, though 95.5% of VAERS reports were nonserious.
Observational (n=211,959)
Yes
What is the safety profile of bivalent COVID-19 mRNA vaccine booster doses in persons aged ≥12 years?
Early safety monitoring of bivalent COVID-19 mRNA boosters shows a safety profile characterized primarily by mild, nonserious injection site and systemic reactions.
On August 31, 2022, the Food and Drug Administration (FDA) authorized bivalent formulations of BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines; these vaccines include mRNA encoding the spike protein from the original (ancestral) strain of SARS-CoV-2 (the virus that causes COVID-19) and from the B.1.1.529(Omicron) variants BA.4 and BA.5 (BA.4/BA.5).These bivalent mRNA vaccines were authorized for use as a single booster dose ≥2 months after completion of primary series or monovalent booster vaccination; Pfizer-BioNTech bivalent booster was authorized for persons aged ≥12 years and Moderna for adults aged ≥18 years.*, † On September 1, 2022, the Advisory Committee on Immunization Practices (ACIP) recommended that all persons aged ≥12 years receive an ageappropriate bivalent mRNA booster dose.§ To characterize the safety of bivalent mRNA booster doses, CDC reviewed adverse events and health impacts reported after receipt of bivalent Pfizer-BioNTech and Moderna booster doses during August 31-October 23, 2022, to v-safe, ¶ a voluntary smartphone-based U.S. safety surveillance system established by CDC to monitor adverse events after COVID-19 vaccination, and the Vaccine Adverse Event Reporting System (VAERS),** a U.S. passive vaccine safety surveillance system managed by CDC and FDA (1).During August 31-October 23, 2022, approximately 14.4 million persons aged ≥12 years received a bivalent Pfizer-BioNTech booster dose, and 8.2 million adults aged ≥18 years received a bivalent Moderna booster dose.† † Among the 211,959 registrants aged ≥12 years who reported receiving a bivalent booster dose to v-safe, injection site and systemic reactions were frequently reported in the week after vaccination (60.8% and 54.8%, respectively); fewer than 1% of v-safe registrants reported receiving medical care.VAERS received 5,542 reports of adverse events after bivalent booster vaccination among persons aged ≥12 years; 95.5% of reports were nonserious and 4.5% were serious events.Health care providers and patients can be reassured that adverse events
Hause et al. (2022) conducted an observational in COVID-19 vaccination (n=211,959). Bivalent COVID-19 mRNA vaccine booster was evaluated on Injection site reactions. Bivalent COVID-19 mRNA booster doses in persons aged ≥12 years were associated with frequent injection site (60.8%) and systemic (54.8%) reactions, though 95.5% of VAERS reports were nonserious.